We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

595 hedge funds and large institutions have $30B invested in Alexion Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 218 increasing their positions, 214 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 45

27% more call options, than puts

Call options by funds: $551M | Put options by funds: $435M

15% more capital invested

Capital invested by funds: $26B → $30B (+$4.01B)

6% more funds holding

Funds holding: 559 → 595 (+36)

2% more repeat investments, than reductions

Existing positions increased: 218 | Existing positions reduced: 214

0% more funds holding in top 10

Funds holding in top 10: 19 → 19 (0)

Holders
595
Holders Change
+36
Holders Change %
+6.44%
% of All Funds
14.83%
Holding in Top 10
19
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.47%
New
88
Increased
218
Reduced
214
Closed
45
Calls
$551M
Puts
$435M
Net Calls
+$117M
Net Calls Change
-$98.3M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$636M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$118M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$83.6M
4
UBS AM
UBS AM
Illinois
+$69.1M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$67.9M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$328M
2
Sands Capital Management
Sands Capital Management
Virginia
-$213M
3
Goldman Sachs
Goldman Sachs
New York
-$183M
4
State Street
State Street
Massachusetts
-$82.3M
5
BlackRock
BlackRock
New York
-$77.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
HCMT
276
Highland Capital Management (Texas)
Texas
$3.08M -$258K -1,900 -8%
QI
277
QS Investors
New York
$3.05M -$228K -1,675 -7%
Jane Street
278
Jane Street
New York
$3M -$3.59M -26,443 -55%
PP
279
Paloma Partners
Connecticut
$2.98M +$2.88M +21,209 New
SCA
280
Secor Capital Advisors
New York
$2.94M -$837K -6,159 -23%
NMERB
281
New Mexico Educational Retirement Board
New Mexico
$2.93M – – –
WAM
282
World Asset Management
Michigan
$2.93M -$33.6K -247 -1%
ID
283
Integral Derivatives
New York
$2.91M -$345K -2,540 -11%
DBG
284
De Burlo Group
Massachusetts
$2.87M -$13.6K -100 -0.5%
CAM
285
Covenant Asset Management
New Jersey
$2.85M -$19.4K -143 -0.7%
OAMG
286
Odey Asset Management Group
United Kingdom
$2.85M – – –
DILIC
287
Dai-ichi Life Insurance Company
Japan
$2.8M – – –
CGH
288
Crossmark Global Holdings
Texas
$2.79M +$2.71M +19,921 New
Natixis Advisors
289
Natixis Advisors
Massachusetts
$2.7M +$314K +2,308 +14%
TAM
290
Taurus Asset Management
New York
$2.6M – – –
COPPSERS
291
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$2.55M +$199K +1,468 +9%
SCM
292
Shelton Capital Management
Colorado
$2.52M – – –
CIC
293
Chase Investment Counsel
Virginia
$2.44M +$2.36M +17,385 New
SMDAM
294
Sumitomo Mitsui DS Asset Management
Japan
$2.43M -$93.1K -685 -4%
WBC
295
Westpac Banking Corp
Australia
$2.41M -$62.9K -463 -3%
SIM
296
Sentry Investment Management
Wisconsin
$2.39M – – –
NB
297
Norinchukin Bank
Japan
$2.33M +$140K +1,029 +7%
GLA
298
Great Lakes Advisors
Illinois
$2.32M +$2.25M +16,557 New
OI
299
Oakbrook Investments
Illinois
$2.31M -$37.4K -275 -2%
DF
300
Donoghue Forlines
Massachusetts
$2.29M +$2.22M +16,332 New
10 11
12
13 14

ALXN Hedge Fund Activity: Q3 2017 in Review

595 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2017, worth a combined $30B — up 15% from $26B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ALXN positions and 45 closed out — a net gain of 43 holders — while 218 added to existing stakes and 214 trimmed.

The largest buyer was Jennison Associates, adding an estimated $636M. The largest seller was Fidelity Investments, cutting an estimated $328M.

  • 595 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2017, up from 559 in Q2 2017.
  • Funds reported $30B of Alexion Pharmaceuticals stock for Q3 2017, up 15% quarter-over-quarter.
  • 88 funds opened new Alexion Pharmaceuticals positions in Q3 2017 and 45 closed out, a net change of +43 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2017 was Jennison Associates, an estimated $636M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2017 was Fidelity Investments, an estimated $328M sold.

Based on aggregated 13F filings for Q3 2017.